Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

127 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
ER+, HER2- advanced breast cancer treated with taselisib and fulvestrant: genomic landscape and associated clinical outcomes.
Chen JW, Jacot W, Cortés J, Krop IE, Dent S, Harbeck N, De Laurentiis M, Diéras V, Im YH, Stout TJ, Schimmoller F, Savage HM, Hutchinson KE, Wilson TR. Chen JW, et al. Among authors: savage hm. Mol Oncol. 2023 Oct;17(10):2000-2016. doi: 10.1002/1878-0261.13416. Epub 2023 Mar 25. Mol Oncol. 2023. PMID: 36892268 Free PMC article.
Phase I Dose-Escalation Study of Taselisib, an Oral PI3K Inhibitor, in Patients with Advanced Solid Tumors.
Juric D, Krop I, Ramanathan RK, Wilson TR, Ware JA, Sanabria Bohorquez SM, Savage HM, Sampath D, Salphati L, Lin RS, Jin H, Parmar H, Hsu JY, Von Hoff DD, Baselga J. Juric D, et al. Among authors: savage hm. Cancer Discov. 2017 Jul;7(7):704-715. doi: 10.1158/2159-8290.CD-16-1080. Epub 2017 Mar 22. Cancer Discov. 2017. PMID: 28331003 Free PMC article. Clinical Trial.
The molecular landscape of high-risk early breast cancer: comprehensive biomarker analysis of a phase III adjuvant population.
Wilson TR, Yu J, Lu X, Spoerke JM, Xiao Y, O'Brien C, Savage HM, Huw LY, Zou W, Koeppen H, Forrest WF, Fridlyand J, Fu L, Tam R, Schleifman EB, Sumiyoshi T, Molinero L, Hampton GM, O'Shaughnessy JA, Lackner MR. Wilson TR, et al. Among authors: savage hm. NPJ Breast Cancer. 2016 Jul 13;2:16022. doi: 10.1038/npjbcancer.2016.22. eCollection 2016. NPJ Breast Cancer. 2016. PMID: 28721382 Free PMC article.
Tumor-Infiltrating Lymphocytes in Patients Receiving Trastuzumab/Pertuzumab-Based Chemotherapy: A TRYPHAENA Substudy.
Ignatiadis M, Van den Eynden G, Roberto S, Fornili M, Bareche Y, Desmedt C, Rothé F, Maetens M, Venet D, Holgado E, McNally V, Kiermaier A, Savage HM, Wilson TR, Cortes J, Schneeweiss A, Willard-Gallo K, Biganzoli E, Sotiriou C. Ignatiadis M, et al. Among authors: savage hm. J Natl Cancer Inst. 2019 Jan 1;111(1):69-77. doi: 10.1093/jnci/djy076. J Natl Cancer Inst. 2019. PMID: 29788230 Free PMC article. Clinical Trial.
Phase I Basket Study of Taselisib, an Isoform-Selective PI3K Inhibitor, in Patients with PIK3CA-Mutant Cancers.
Jhaveri K, Chang MT, Juric D, Saura C, Gambardella V, Melnyk A, Patel MR, Ribrag V, Ma CX, Aljumaily R, Bedard PL, Sachdev JC, Dunn L, Won H, Bond J, Jones S, Savage HM, Scaltriti M, Wilson TR, Wei MC, Hyman DM. Jhaveri K, et al. Among authors: savage hm. Clin Cancer Res. 2021 Jan 15;27(2):447-459. doi: 10.1158/1078-0432.CCR-20-2657. Epub 2020 Nov 4. Clin Cancer Res. 2021. PMID: 33148674 Clinical Trial.
127 results